Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Friday, May 8th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.80) per share for the quarter, up from their prior forecast of ($0.94). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($3.33) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($3.50) EPS, FY2028 earnings at ($4.52) EPS, FY2029 earnings at ($2.56) EPS and FY2030 earnings at $0.00 EPS.
ARTV has been the subject of a number of other reports. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, May 4th. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, Cantor Fitzgerald boosted their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.25.
Artiva Biotherapeutics Price Performance
Shares of Artiva Biotherapeutics stock opened at $10.60 on Tuesday. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $14.53. The firm has a market capitalization of $262.03 million, a price-to-earnings ratio of -2.99 and a beta of 2.86. The business has a 50-day simple moving average of $7.81 and a 200 day simple moving average of $5.43.
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07).
Institutional Trading of Artiva Biotherapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC boosted its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after buying an additional 37,053 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $341,000. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $174,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $112,000.
More Artiva Biotherapeutics News
Here are the key news stories impacting Artiva Biotherapeutics this week:
- Positive Sentiment: Cantor Fitzgerald lifted its price target on Artiva Biotherapeutics to $40 and kept an overweight rating, signaling strong upside potential. Cantor Fitzgerald Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
- Positive Sentiment: Wedbush also raised its target to $40 and maintained an outperform rating, reinforcing bullish sentiment around the stock. Wedbush Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
- Neutral Sentiment: HC Wainwright increased FY2026, Q2 2026, Q3 2026, Q4 2026, and FY2030 EPS estimates, suggesting improving earnings visibility. HC Wainwright estimate updates for Artiva Biotherapeutics
- Negative Sentiment: HC Wainwright lowered FY2027, FY2028, and FY2029 EPS estimates, which tempers the longer-term optimism. HC Wainwright estimate revisions for Artiva Biotherapeutics
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
See Also
- Five stocks we like better than Artiva Biotherapeutics
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
